{"id":556998,"date":"2021-08-10T18:30:01","date_gmt":"2021-08-10T18:30:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=556998"},"modified":"2021-08-10T18:30:01","modified_gmt":"2021-08-10T18:30:01","slug":"cholangiocarcinoma-market-analysis-market-size-share-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cholangiocarcinoma-market-analysis-market-size-share-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_556998.html","title":{"rendered":"Cholangiocarcinoma Market Analysis, Market Size &#038; Share, Epidemiology, Leading Companies And Competitive Analysis By DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1628593681.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Cholangiocarcinoma Market Analysis, Market Size &amp; Share, Epidemiology, Leading Companies And Competitive Analysis By DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1628593681.png\" alt=\"Cholangiocarcinoma Market Analysis, Market Size &amp; Share, Epidemiology, Leading Companies And Competitive Analysis By DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Cholangiocarcinoma (CCA) &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Cholangiocarcinoma (CCA), historical and forecasted epidemiology as well as the Cholangiocarcinoma (CCA) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>DelveInsight has launched a new report on<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">&#8220;Cholangiocarcinoma &#8211; Market Insights, Epidemiology, and Market Forecast-2030&rdquo;.<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">&ldquo;Cholangiocarcinoma &ndash; Market Insights, Epidemiology, and Market Forecast-2030&Prime;<\/a>report delivers an in-depth understanding of the Cholangiocarcinoma, historical and forecasted epidemiology as well as the&nbsp; Cholangiocarcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/3bc36a5b974a5758eec889cac99ee789.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Report:<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">As per DelveInsight estimates, the total diagnosed incident population of Cholangiocarcinoma (CCA) in the 7MM ranges 18,470 in 2017. Among all the countries, the estimates show a higher incidence of Cholangiocarcinoma (CCA) in the United States with 6,768 cases in 2017.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Among the EU5 countries, Germany had the highest incident population of Cholangiocarcinoma (CCA) with 4,471 cases, followed by Italy and the United Kingdom. On the other hand, Spain had the lowest incident population. As per our estimates, Japan had 4,287 incident cases of Cholangiocarcinoma (CCA) in 2017.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">As per DelveInsight insights, the incidence rate varied based on type-specific cases and the estimates showed an increasing trend in the Intrahepatic CCA cases, while Extrahepatic CCA showed a decreasing trend or in some are stable cases.<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>Key benefits of the report:<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Cholangiocarcinoma market report covers a descriptive overview and comprehensive insight of the Cholangiocarcinoma epidemiology and Cholangiocarcinoma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The Cholangiocarcinoma market report provides insights on the current and emerging therapies.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Cholangiocarcinoma market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The Cholangiocarcinoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Cholangiocarcinoma market.<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>Got queries? Click here to know more about <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Cholangiocarcinoma Market Landscape.<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Cholangiocarcinoma Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">A cancer in the slender tubes that carry bile, the digestive fluid, through the liver. It&#8217;s a rare but aggressive form of cancer.Symptoms include yellow skin and eyes (jaundice), intensely itchy skin and stool that&#8217;s white in colour.Treatment may include surgery, chemotherapy and radiation.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The key players driving the Cholangiocarcinoma market:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Janssen Pharmaceutica<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Roche<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Loxo Oncology\/ Bayer<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bayer<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Basilea Pharmaceutica<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Delcath Systems<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">QED Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Incyte Corporation<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Agios Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">And others<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The launch of the emerging therapies is expected to significantly impact the Cholangiocarcinoma treatment scenario in the upcoming years.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Drug covered:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Erdafitinib&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Entrectinib&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Larotrectinib&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Regorafenib&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Derazantinib&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Melphalan&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Infigratinib&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pemigatinib&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Vosidenib&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">And others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. SWOT analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Cholangiocarcinoma Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Cholangiocarcinoma Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Cholangiocarcinoma Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Cholangiocarcinoma Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Country-Specific Patient Population of Cholangiocarcinoma<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Cholangiocarcinoma Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Cholangiocarcinoma Emerging Therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Cholangiocarcinoma Market Outlook<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Country-Wise Cholangiocarcinoma Market Analysis (2017&ndash;2030)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Market drivers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Market barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Cholangiocarcinoma Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports:<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cholangiocarcinoma-cca-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Cholangiocarcinoma Pipeline&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&#8220;Cholangiocarcinoma Pipeline Insight, 2021&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the&nbsp; Cholangiocarcinoma market. A detailed picture of the&nbsp; Cholangiocarcinoma pipeline landscape is provided, which includes the disease overview and&nbsp; Cholangiocarcinoma treatment guidelines.<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cholangiocarcinoma-cca-epidemiology-forecast\">Cholangiocarcinoma Epidemiology<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8216;Cholangiocarcinoma Epidemiology Forecast to 2030&#8217; report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=cholangiocarcinoma-market-analysis-market-size-share-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=cholangiocarcinoma-market-analysis-market-size-share-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s &#8220;Cholangiocarcinoma (CCA) &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Cholangiocarcinoma (CCA), historical and forecasted epidemiology as well as the Cholangiocarcinoma (CCA) market trends in the United States, EU5 &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/cholangiocarcinoma-market-analysis-market-size-share-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_556998.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-556998","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/556998","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=556998"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/556998\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=556998"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=556998"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=556998"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}